TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02695576

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Examination by physiotherapist, motivation of the patient, training in body awareness, physical activity/Qigong, training in water, outdoor pole work, circle training, stabilization training, massage, stretching, lessons and practice in ergonomics.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Examination by physiotherapist, motivation of the patient, training in body awareness, physical activity/Qigong, training in water, outdoor pole work, circle training, stabilization training, massage, stretching, lessons and practice in ergonomics.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: Individual and group lessons performed by psychologists.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Individual and group lessons performed by psychologists.
Study: NCT02672618

Intervention type: OTHER
Description: The IRS system is capable of precisely measuring and storing real-time thermal images with a resolution of 320×240 pixels (IRS S6md Shanghai,China). The camera has Focal Plane Array (FPA), Uncooled microbolometer detector, with a thermal sensitivity of 0.05 ℃ at 20℃ to 30℃. The thermal images were captured at a distance of one meter from the various body regions namely face and the images were analyzed by thermal software（version 1.0）.

Intervention type: OTHER
Description: The IRS system is capable of precisely measuring and storing real-time thermal images with a resolution of 320×240 pixels (IRS S6md Shanghai,China). The camera has Focal Plane Array (FPA), Uncooled microbolometer detector, with a thermal sensitivity of 0.05 ℃ at 20℃ to 30℃. The thermal images were captured at a distance of one meter from the various body regions namely face and the images were analyzed by thermal software（version 1.0）.

Intervention type: OTHER
Description: The IRS system is capable of precisely measuring and storing real-time thermal images with a resolution of 320×240 pixels (IRS S6md Shanghai,China). The camera has Focal Plane Array (FPA), Uncooled microbolometer detector, with a thermal sensitivity of 0.05 ℃ at 20℃ to 30℃. The thermal images were captured at a distance of one meter from the various body regions namely face and the images were analyzed by thermal software（version 1.0）.
Study: NCT03954249

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erecto Spinae nerve block
Description: The ESPB is a myofascial block alternative to the paravertebral block. It is performed by injecting local anesthetic in the plane between the erector spinae muscle and the spinal transverse process. The ESPB is thought to be safer than the paravertebral block because the transverse process acts as a barrier to the pleura. It has been postulated that local anesthetic spread reaches the paravertebral space and in fact, cadaveric studies have shown dye spreading to involve the ventral and dorsal rami of spinal nerves.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Analgesia
Description: Patients in the control group will receive standard 100mg pregabalin PO, midazolam 2mg IV, fentanyl 100mcg IV.
Study: NCT00294684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Schedule and dosing of corticosteroids following portoenterostomy in infants with biliary atresia are listed below.~Days 1-3: Methylprednisolone, IV-4mg/kg/day, divided BID Days 4-7: Prednisolone, PO-4mg/kg/day, divided BID Week 2: 4 mg/kg/day, divided BID Week 3: 2 mg/kg/day, divided BID Week 4: 2 mg/kg/day, divided BID Week 5: 1 mg/kg/day, once a day Week 6: 1 mg/kg/day, once a day Week 7: 0.8 mg/kg/day, once a day Week 8: 0.6 mg/kg/day, once a day Week 9: 0.4 mg/kg/day, once a day Week 10: 0.2 mg/kg/day, once a day Week 11: 0.1 mg/kg/day, once a day Week 12-13: 0.1 mg/kg/day, every other day Week 14: Stop
Study: NCT02188511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A
Description: 90 minutes prior to the bronchoscopy on day 8, the subject will be asked to inhale 10 puffs of a Blu brand e-cigarette (for the nicotine-containing e-cigarette, this is approximately equivalent to \< 1 cigarette). At 30 minutes prior to the bronchoscopy procedure if the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B
Description: On days 7 and 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group C
Description: On days 6 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group D
Description: On days 5 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group E
Description: On days 4 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).~Exposure to e-cigarettes will be limited to the nicotine equivalent of 1/2 pack of cigarettes to mitigate the risk of addiction to nicotine.
Study: NCT03003572

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples will be collected at inclusion to determine anti-Ro/SSA IgE titers (Enzyme Linked ImmunoSorbent Assay ELISA).
Study: NCT01798667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8031
Study: NCT02943070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rezum System
Description: The Rezūm System treats patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death. The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure.
Study: NCT04347512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine and azithromycin treatment arm.
Description: Patient allocated in this arm receive hydroxychloroquine and azithromycin for 5 days.~For hydroxychloroquine, there is a loading dose of 800 mg per day at D1, followed by 400 mg per day D2-D5.~For azithromycin, there is a loading dose of 500 mg per day at D1, followed by 250 mg per day D2-D5.~Every patient receive as well antibiotic (ceftriaxone 1-2 g per day IV), and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Patient allocated in this arm receive hydroxychloroquine for 5 days. For hydroxychloroquine, there is a loading dose of 800 mg per day at D1, followed by 400 mg per day D2-D5.~Every patient receives as well antibiotic (ceftriaxone 1-2 g per day IV), and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control arm
Description: In this arm, no experimental treatment is prescribed. Patients receive IV antibiotics and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc).
Study: NCT04830839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery after Stress Toolkit (ReSeT)
Description: ReSeT involves online modules with parallel videoconferencing sessions. ReSeT integrates two evidence-based treatment methods: cognitive behavioral therapy coping skills (coping CBT) and direct exposure to trauma reminders through a trauma narrative.
Study: NCT01817842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile EX cessation support
Description: Mobile EX cessation support is designed to enhance the Washington D.C. Quitline (DCQL) by giving participants the ability track their cessation attempt on a phone-based app and thus create a profile documenting their progress and set-backs over the days or weeks in between QL contacts. Participants receive summary information and graphics that help them understand what is working best for them. Participants also receive 24-hr, momentary access to a set of interactive cessation tools on their phone.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DC Quitline Support
Description: Participants assigned to standard DC Quitline programming receive 6 proactive QL counseling sessions and optional, free nicotine replacement therapy (NRT).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DC Quitline Support
Description: Participants assigned to standard DC Quitline programming receive 6 proactive QL counseling sessions and optional, free nicotine replacement therapy (NRT).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Device Control
Description: Mobile phone for use during cessation attempt but with no mEX support components
Study: NCT03447405

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dino Egg
Description: DINO EGG speakers, a NICU-safe and developmentally appropriate music player that delivers parent's voice to the bedside of NICU infants. The device passed NCH NICU-safe products committee and has been used in the clinical setting delivering clinical music therapy services (available at bedside to play parents' voice).
Study: NCT02044952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine, Tripterygium glycosides
Description: tripterygium glycosides: 2mg/kg/d, oral Mesalazine: 4g/d, oral
Study: NCT02740244

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active iTBS
Description: Transcranial magnetic stimulation. MagProX100 (MagVenture, Denmark) with a figure-eight coil (MCF-B65)
Study: NCT02325518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution
Study: NCT02740244

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham iTBS
Description: Transcranial magnetic stimulation. MagProX100 (MagVenture, Denmark) with a sham figure-eight coil (MCF-P-B65)
Study: NCT04387006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OMT
Description: OMT techniques were focused on correcting the dysfunctions found during the initial physical examination and included articular and myofascial techniques, balanced ligamentous tension, visceral manipulations and osteopathy in the cranial field

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MP
Description: MP treatment was performed by the same osteopaths who performed OMT and was carried out in the same hospital setting. P treatment consisted of a passive touch without joint mobilization in a protocolled order. The osteopaths were standing next to the bed, they touched lumbar and dorsal spine of the subjects in prone position for 10 minutes, and then in supine position, they touched for 10 minutes the shoulders, the hips, then the neck, the sternum and the chest were touched for 5 minutes each. Another researcher on the placebo protocol specifically trained the osteopaths.
Study: NCT03198767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 50 mg tablets. Open-label, bulk, blister-pack.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 50 mg tablets. Open-label, bulk, blister-pack.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 50 mg tablets. Open-label, bulk, blister-pack.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 50 mg tablets. Open-label, bulk, blister-pack.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 50 mg tablets. Open-label, bulk, blister-pack.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 50 mg tablets. Open-label, bulk, blister-pack.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 50 mg tablets. Open-label, bulk, blister-pack.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate 50%
Description: 50% carbohydrate in breakfast meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate 50%
Description: 50% carbohydrate in breakfast meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate 50%
Description: 50% carbohydrate in breakfast meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate 50%
Description: 50% carbohydrate in breakfast meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate 50%
Description: 50% carbohydrate in breakfast meal
Study: NCT02325518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subject's habitual PGA monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subject's habitual PGA monotherapy
Study: NCT01004094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: simple goal setting
Description: This group will set goals only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: goal setting plus action intentions
Description: This group will set goals and form action intentions (plans)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: goal setting plus coping intentions
Description: This group will set goals and form coping intentions (plans)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: goal setting plus action intentions plus coping intentions
Description: This group will set goals and form action intentions and coping intentions
Study: NCT02249312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03198767

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate 50%
Description: 50% carbohydrate in breakfast meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate 25%
Description: 25% carbohydrate in breakfast meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate 25%
Description: 25% carbohydrate in breakfast meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate 25%
Description: 25% carbohydrate in breakfast meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate 8%
Description: 8% carbohydrate in breakfast meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate 0%
Description: 0% carbohydrate in breakfast meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate 0%
Description: 0% carbohydrate in breakfast meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate 0%
Description: 0% carbohydrate in breakfast meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium
Description: Powder 6 grams

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium
Description: Powder 6 grams

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium
Description: Powder 6 grams

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: Liquid 1 gram (4 mL equivalent sugar free)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: Liquid 1 gram (4 mL equivalent sugar free)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: Liquid 1 gram (4 mL equivalent sugar free)
Study: NCT01819363

Intervention type: PROCEDURE
Intervention: Pleural elastance
Description: The pleural pressure level will be zero at the time of the insertion site of the drain on the skin. The pleural pressure is set to the value measured at end-expiration. The pleural pressure is measured at baseline, after withdrawal of 10 ml of liquid and thereafter every 400 ml of pleural effusion evacuated to the pressure to be negative, from that moment the measurement will occur every 200 ml of pleural effusion drained to obtain 800 ml of liquid. Patients that are removed less than 800 ml of liquid will be excluded from the protocol. The pleural elastance is then calculated in cm H2O / L and the data placed in a pressure curve by volume.
Study: NCT01080924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency ultrasound spectroscopy after broncholysis
Description: Low frequency ultrasound spectroscopy is a novel non-invasive approach to real-time diagnostics of the lungs. Low frequency ultrasound at 10 to 1000 kHz permits monitoring of the air and water contents of the human thorax.
Study: NCT02039167

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Left atrial appendage occlusion
Description: Percutaneous left atrial appendage closure using the WATCHMAN device.
Study: NCT03391830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin-Ascorbic acid
Description: atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01798667

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of DA-8031, undistinguishable
Study: NCT03351699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4250
Description: MK-4250 tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4250
Description: MK-4250 tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4250
Description: MK-4250 tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4250
Description: MK-4250 tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4250
Description: MK-4250 tablets for oral administration
Study: NCT02697201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid
Description: 0.55 ml/kg/h

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intralipid
Description: 0.55 ml/kg/h
Study: NCT00294684

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Schedule and dosing of placebo following portoenterostomy in infants with biliary atresia:~Days 1-3: IV - normal saline 4 mg/kg/day, divided BID Days 4-7: PO placebo 4 mg/kg/day, divided BID Week 2: PO placebo 4 mg/kg/day, divided BID Week 3: PO placebo 2 mg/kg/day, divided BID Week 4: PO placebo 2 mg/kg/day, divided BID Week 5: PO placebo 1 mg/kg/day, once a day Week 6: PO placebo 1 mg/kg/day, once a day Week 7: PO placebo 0.8 mg/kg/day, once a day Week 8: PO placebo 0.6 mg/kg/day, once a day Week 9: PO placebo 0.4 mg/kg/day, once a day Week 10: PO placebo 0.2 mg/kg/day, once a day Week 11: PO placebo 0.1 mg/kg/day, once a day Week 12-13: PO placebo 0.1 mg/kg/day, once a day every other day Week 14: Stop
Study: NCT02090465

Intervention type: DRUG
Intervention: Ingenol Mebutate
Description: No intervention: observation of routine use of Picato®
Study: NCT02697201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 0.55 ml/kg/h for

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: 0.55 ml/kg/h for
Study: NCT04350541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: Exercise with high-intensity intervals followed by active rest
Study: NCT01085019

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cinnamon
Description: 2.8g/day of cinnamon in capsules during 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oregano
Description: 2.8g/day of oregano in capsules during 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginger
Description: 2.8g/day of ginger in capsules during 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rosemary
Description: 2.8g/day of rosemary in capsules during 4 weeks.
Study: NCT04350541

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous aerobic training
Description: Interval Moderate-intensity aerobic training without intervals
Study: NCT00212251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: moderate exercise and healthy, low-fat diet